203 related articles for article (PubMed ID: 37286997)
1. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
J Transl Med; 2023 Jun; 21(1):367. PubMed ID: 37286997
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Chimeric Antigen Receptor Modified T Cells Expressing scFv-IL-13Rα2 after Radiolabeling with 89Zirconium Oxine for PET Imaging.
Leland P; Kumar D; Nimaggada S; Bauer SR; Puri RK; Joshi BH
Res Sq; 2023 Jan; ():. PubMed ID: 36711796
[TBL] [Abstract][Full Text] [Related]
3. PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with
Weist MR; Starr R; Aguilar B; Chea J; Miles JK; Poku E; Gerdts E; Yang X; Priceman SJ; Forman SJ; Colcher D; Brown CE; Shively JE
J Nucl Med; 2018 Oct; 59(10):1531-1537. PubMed ID: 29728514
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.
Leland P; Degheidy H; Lea A; Bauer SR; Puri RK; Joshi BH
Clin Transl Med; 2024 May; 14(5):e1664. PubMed ID: 38685487
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging.
Lee SH; Soh H; Chung JH; Cho EH; Lee SJ; Ju JM; Sheen JH; Kim H; Oh SJ; Lee SJ; Chung J; Choi K; Kim SY; Ryu JS
PLoS One; 2020; 15(1):e0223814. PubMed ID: 31910217
[TBL] [Abstract][Full Text] [Related]
6. A kit formulation for the preparation of [
Man F; Khan AA; Carrascal-Miniño A; Blower PJ; T M de Rosales R
Nucl Med Biol; 2020; 90-91():31-40. PubMed ID: 32979725
[TBL] [Abstract][Full Text] [Related]
7. Spatio-temporal biodistribution of
Sta Maria NS; Khawli LA; Pachipulusu V; Lin SW; Zheng L; Cohrs D; Liu X; Hu P; Epstein AL; Jacobs RE
Sci Rep; 2021 Jul; 11(1):15077. PubMed ID: 34302002
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
[TBL] [Abstract][Full Text] [Related]
9. (89)Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies.
Sato N; Wu H; Asiedu KO; Szajek LP; Griffiths GL; Choyke PL
Radiology; 2015 May; 275(2):490-500. PubMed ID: 25706654
[TBL] [Abstract][Full Text] [Related]
10. Imaging of cell-based therapy using
Kurebayashi Y; Choyke PL; Sato N
Nanotheranostics; 2021; 5(1):27-35. PubMed ID: 33391973
[TBL] [Abstract][Full Text] [Related]
11.
Sato N; Stringaris K; Davidson-Moncada JK; Reger R; Adler SS; Dunbar C; Choyke PL; Childs RW
Clin Cancer Res; 2020 Jun; 26(11):2573-2581. PubMed ID: 32034075
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of
Wang XY; Wang Y; Wu Q; Liu JJ; Liu Y; Pan DH; Qi W; Wang LZ; Yan JJ; Xu YP; Wang GJ; Miao LY; Yu L; Yang M
Acta Pharmacol Sin; 2021 May; 42(5):824-831. PubMed ID: 32901086
[TBL] [Abstract][Full Text] [Related]
13. Tracking of NK Cells by Positron Emission Tomography Using
Sato N; Szajek LP; Choyke PL
Methods Mol Biol; 2022; 2463():153-161. PubMed ID: 35344173
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution of 89Zr-oxine-labeled human bone marrow-derived mesenchymal stem cells by micro-PET/computed tomography imaging in Sprague-Dawley rats.
Wang S; Wang Y; Xu B; Qin T; Lv Y; Yan H; Shao Y; Fang Y; Zheng S; Qiu Y
Nucl Med Commun; 2022 Jul; 43(7):834-846. PubMed ID: 35438673
[TBL] [Abstract][Full Text] [Related]
15. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.
Krebs S; Ahad A; Carter LM; Eyquem J; Brand C; Bell M; Ponomarev V; Reiner T; Meares CF; Gottschalk S; Sadelain M; Larson SM; Weber WA
J Nucl Med; 2018 Dec; 59(12):1894-1900. PubMed ID: 29903928
[TBL] [Abstract][Full Text] [Related]
16. Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
J Transl Med; 2023 Sep; 21(1):636. PubMed ID: 37726828
[No Abstract] [Full Text] [Related]
17. Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model.
Kim SY; Soh H; Jung JH; Cho EH; Kim H; Ju JM; Sheen JH; Lee SJ; Oh SJ; Lee SJ; Chung J; Ryu JS
Radiology; 2024 Feb; 310(2):e231406. PubMed ID: 38411517
[TBL] [Abstract][Full Text] [Related]
18. Optimisation of the Synthesis and Cell Labelling Conditions for [
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samén E; Carlsten M; Holmin S; Tran TA
Mol Imaging Biol; 2021 Dec; 23(6):952-962. PubMed ID: 34231103
[TBL] [Abstract][Full Text] [Related]
19. Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling.
Bansal A; DeGrado TR; Pandey MK
J Vis Exp; 2023 Oct; (200):. PubMed ID: 37955388
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.
Yin Y; Boesteanu AC; Binder ZA; Xu C; Reid RA; Rodriguez JL; Cook DR; Thokala R; Blouch K; McGettigan-Croce B; Zhang L; Konradt C; Cogdill AP; Panjwani MK; Jiang S; Migliorini D; Dahmane N; Posey AD; June CH; Mason NJ; Lin Z; O'Rourke DM; Johnson LA
Mol Ther Oncolytics; 2018 Dec; 11():20-38. PubMed ID: 30306125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
